FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

肽库

FDA监管成分

该成分是FDA批准或监管的。未经有效处方购买可能违反联邦法律。请在您所在地区核实所有法律规定。

Tirzepatide

Mounjaro / Zepbound

Weight Loss & Metabolic

Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly, approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. It represents a significant advancement over single-agonist GLP-1 drugs like semaglutide, demonstrating superior weight loss and glycemic control in head-to-head trials. The molecule is a 39-amino acid synthetic peptide with a C20 fatty diacid moiety enabling once-weekly dosing through albumin binding.

作用机制

Dual GIP/GLP-1 receptor agonist. Activates both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors simultaneously. Produces greater weight loss and glycemic control than single-receptor agonists.

研究协议

仅供研究使用,非医疗建议。

Research protocols start at 2.5mg weekly for 4 weeks, escalating through 5mg, 7.5mg, 10mg, 12.5mg, to a maximum of 15mg weekly.

研究笔记

Clinical Research Status

Tirzepatide received FDA approval for type 2 diabetes (Mounjaro) in May 2022 and for chronic weight management (Zepbound) in November 2023. The SURMOUNT clinical program demonstrated unprecedented weight loss of up to 22.5% at the highest dose in non-diabetic obese adults. Ongoing trials are investigating applications in heart failure with preserved ejection fraction (HFpEF), obstructive sleep apnea, and MASH/NASH.

Key Published Findings

The SURPASS-2 trial showed tirzepatide 15mg was superior to semaglutide 1mg for both HbA1c reduction (-2.46% vs -1.86%) and weight loss (-12.4kg vs -6.2kg). SURMOUNT-1 demonstrated that 22.5% of participants on the 15mg dose achieved greater than 25% body weight loss at 72 weeks. The SURMOUNT-4 trial confirmed that weight regain occurs upon discontinuation, with participants regaining approximately 14% of lost weight after stopping treatment.

Safety Profile

The most common adverse events are gastrointestinal: nausea (12-33%), diarrhea (12-21%), and vomiting (5-12%), generally mild-to-moderate and decreasing with continued use. A boxed warning exists for thyroid C-cell tumors based on rodent studies, though human relevance is uncertain. Pancreatitis, gallbladder events, and hypoglycemia (when combined with sulfonylureas or insulin) are less common but clinically significant risks.

Drug Interactions & Contraindications

Tirzepatide slows gastric emptying, potentially affecting absorption of oral medications, particularly oral contraceptives (backup contraception recommended for 4 weeks after initiation or dose increase). Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Dose adjustments may be needed for insulin and sulfonylureas to prevent hypoglycemia when used in combination.

Comparison to Related Compounds

Head-to-head data from SURPASS-2 shows tirzepatide's superiority over semaglutide for both weight loss and glycemic control, likely attributable to the additive GIP receptor agonism. Unlike semaglutide which is purely a GLP-1 agonist, tirzepatide's dual mechanism may better preserve lean mass during weight loss based on preliminary body composition data. Retatrutide (Eli Lilly's triple agonist adding glucagon receptor activity) represents the next evolution, showing up to 24.2% weight loss in Phase 2 trials.

Community Observations

Available in escalating doses from 2.5mg to 15mg, with recommended titration over 20+ weeks to minimize GI side effects. Supply constraints have been a persistent issue since launch, with many patients experiencing difficulty obtaining prescriptions. Cost without insurance is approximately $1,000-1,100/month, though manufacturer savings programs and compounding pharmacies have expanded access.

半衰期

~5 days

复溶

Bacteriostatic water (BAC)

存储

冻干

Room temperature up to 24 months. Protect from light.

复溶后

Refrigerate 2-8C. Use within 21 days.

美国法律状态

FDA-approved (Rx only)

又称作

MounjaroZepbound

常见问题

什么是 Tirzepatide?

Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly, approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. It represents a significant advancement over single-agonist GLP-1 drugs like semaglutide, demonstrating superior weight loss and glycemic control in head-to-head trials. The molecule is a 39-amino acid synthetic peptide with a C20 fatty diacid moiety enabling once-weekly dosing through albumin binding.

Tirzepatide 如何起作用?

Dual GIP/GLP-1 receptor agonist. Activates both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors simultaneously. Produces greater weight loss and glycemic control than single-receptor agonists.

Tirzepatide 在美国的监管状态是什么?

FDA-approved (Rx only)

Tirzepatide 的半衰期是多少?

~5 days

Tirzepatide 还有哪些名称?

Mounjaro, Zepbound

Peptide Contacts仅提供基于研究的摘要,仅供信息参考。我们不托管、分发或支持供应商文档。所有证书分析、GMP证书和供应商通信必须由买家直接请求并验证。本平台上任何内容均不构成法律、医疗或专业建议。用户在购买任何研究化学品之前应自行核实供应商资质,并确保遵守所有适用的当地、州及联邦法律法规,承担全部法律责任。

阅读完整免责声明